Houghton PJ - Search Results

1

Houghton PJ. Houghton PJ. Clin Cancer Res. 2010 Mar 1;16(5):1368-72. doi: 10.1158/1078-0432.CCR-09-1314. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179227 Free PMC article. Review.

2

Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.

Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA, Tan M, Friedman HS, Brent TP. Houghton PJ, et al. Clin Cancer Res. 2000 Oct;6(10):4110-8. Clin Cancer Res. 2000. PMID: 11051264

3

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ. Dudkin L, et al. Among authors: houghton pj. Clin Cancer Res. 2001 Jun;7(6):1758-64. Clin Cancer Res. 2001. PMID: 11410517

4

Testing of new agents in childhood cancer preclinical models: meeting summary.

Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Houghton PJ, et al. Clin Cancer Res. 2002 Dec;8(12):3646-57. Clin Cancer Res. 2002. PMID: 12473573

5

mTOR as a target for cancer therapy.

Houghton PJ, Huang S. Houghton PJ, et al. Curr Top Microbiol Immunol. 2004;279:339-59. doi: 10.1007/978-3-642-18930-2_20. Curr Top Microbiol Immunol. 2004. PMID: 14560967 Review.

6

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.

Wagner LM, Crews KR, Iacono LC, Houghton PJ, Fuller CE, McCarville MB, Goldsby RE, Albritton K, Stewart CF, Santana VM. Wagner LM, et al. Among authors: houghton pj. Clin Cancer Res. 2004 Feb 1;10(3):840-8. doi: 10.1158/1078-0432.ccr-03-0175. Clin Cancer Res. 2004. PMID: 14871959 Clinical Trial.

7

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P. Houghton PJ, et al. Cancer Res. 2004 Apr 1;64(7):2333-7. doi: 10.1158/0008-5472.can-03-3344. Cancer Res. 2004. PMID: 15059881

8

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.

Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, Smykla R, Lee FY, Houghton PJ. Peterson JK, et al. Among authors: houghton pj. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8. doi: 10.1158/1078-0432.CCR-05-0740. Clin Cancer Res. 2005. PMID: 16203787

9

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Houghton PJ, et al. Pediatr Blood Cancer. 2008 Apr;50(4):799-805. doi: 10.1002/pbc.21296. Pediatr Blood Cancer. 2008. PMID: 17635004

10

Phase I study of everolimus in pediatric patients with refractory solid tumors.

Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL. Fouladi M, et al. Among authors: houghton pj. J Clin Oncol. 2007 Oct 20;25(30):4806-12. doi: 10.1200/JCO.2007.11.4017. J Clin Oncol. 2007. PMID: 17947729 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

591 results

Search Page

Filters